<DOC>
	<DOCNO>NCT01028313</DOCNO>
	<brief_summary>There clear need effective , steroid-sparing agent management chronic graft-versus-host disease ( GVHD ) . Thus , agent like Histone deacetylase ( HDAC ) inhibitor , potential decrease pro-inflammatory event lead GVHD without affect graft-versus-leukemia ( GVL ) , may central role prevention treatment GVHD . This study look efficacy panobinostat ( LBH589 ) , HDAC inhibitor , treatment patient chronic GVHD fail corticosteroid . In group patient , effective steroid-sparing option limit usually associate profound immunosuppression decrease GVL effect .</brief_summary>
	<brief_title>A Study Panobinostat ( LBH589 ) Second-Line Therapy Patients With Chronic Graft-Versus-Host Disease</brief_title>
	<detailed_description>Chronic GVHD autoimmune , inflammatory disorder occur majority patient experience acute GVHD . Long-term corticosteroid still standard therapy chronic GVHD . Corticosteroids associate high morbidity non-relapse mortality . In addition , corticosteroid broadly immunosuppressive also decrease GVL effect increase incidence relapse . There clear need effective , steroid-sparing agent management chronic GVHD . Thus , agent like HDAC inhibitor , potential decrease pro-inflammatory event lead GVHD without affect GVL , may central role prevention treatment GVHD . This study look efficacy panobinostat ( LBH589 ) , HDAC inhibitor , treatment patient chronic GVHD fail corticosteroid . In group patient , effective steroid-sparing option limit usually associate profound immunosuppression decrease GVL effect .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Chronic GvHD follow allogeneic HSCT source ( bone marrow , peripheral blood , cord blood stem cell ) , donor type ( relate , unrelated , mismatch ) type malignancy . Chronic GvHD define accord NIH Consensus Criteria . 2 . Patients must inadequate response treatment steroid calcineurin inhibitor . Patients must treat initial dose least 1 mg/kg/day methylprednisolone ( MP ) equivalent combination tacrolimus cyclosporine must fulfill definition steroid refractoriness resistance . Steroid refractoriness resistance define : 1 . Lack response 1 month treatment MP , include 15 day least 0.5 mg/kg/day . 2 . Worsening exist GvHD new organ involvement time follow one week initiation MP 1 mg/kg/day . 3 . Reflare worsen GvHD time steroid taper . 4 . Patients receive drug treatment chronic GvHD steroid calcineurin inhibitor ( i.e. , cyclosporine tacrolimus ) . 3 . Patient must evidence primary disease relapse . 4 . An ECOG ( Eastern Cooperative Oncology Group ) performance status ≤2 5 . Baseline MUGA ECHO must demonstrate leave ventricular ejection fraction ( LVEF ) ≥40 % . 6 . No uncontrolled arrhythmia symptom heart disease . 7 . FEV1 , FVC , DLCO ≥40 % . 8 . Laboratory value follow : white blood cell ≥2500/mm³ ; absolute neutrophil count ( ANC ) ≥1,000/mm³ ; hemoglobin ≥9.5 g % ; platelet ≥50,000/mm³ ; total bilirubin &lt; 3 x upper limit normal ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤5 × institutional upper limit normal ( ULN ) ; creatinine &lt; 1.5 × ULN creatinine clearance ≥ 50 ml/min ; serum potassium ≥ LLN ; serum sodium ≥ LLN ; serum calcium WNL ; serum phosphorus WNL ; serum magnesium WNL ; 9 . Patients elevate alkaline phosphatase due bone metastasis may enrol . 10 . TSH free T4 within normal limit ( clinically euthyroid patient permit receive thyroid supplement treat underlying hypothyroidism ) . 11 . Age ≥ 18 year , male female . 12 . Ability understand willingness sign write informed consent document . 1 . Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer . 2 . Patients need valproic acid medical condition study ≤5 day prior first panobinostat treatment . 3 . Use prior immunosuppressant steroid calcineurin inhibitor ( i.e . cyclosporine tacrolimus ) . 4 . Chronic active hepatitis cirrhosis . 5 . Impaired cardiac function include follow : Patients congenital long QT syndrome ; Patients history presence sustain ventricular tachyarrhythmias ; Patients history ventricular fibrillation Torsades de Pointes ; Patients bradycardia define HR &lt; 50 bpm . Patients pacemaker eligible HR ≥50 bpm . Patients myocardial infarction unstable angina ≤6 month prior start study drug ; Right bundle branch block plus leave anterior hemiblock ( bifasicular block ) ; Screening ECG QTc &gt; 450 msec ; Congestive heart failure ( CHF ) &gt; New York Heart Association ( NYHA ) Class II ( see Appendix D ) . 6 . Concomitant use drug risk cause Torsades de Pointes ( see Appendix A ) . 7 . Other concurrent severe and/or uncontrolled medical condition . 8 . Any condition impair patient 's ability swallow whole pill gastrointestinal ( GI ) tract disease involve inability take oral medication , malabsorption syndrome , requirement intravenous ( IV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Chronic Graft-Versus-Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>LBH589</keyword>
	<keyword>Panobinostat</keyword>
</DOC>